AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21901296
Drug: Intravitreal ranibizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal ranibizumab injections (3 monthly injections)
Trial: 21903775
Drug: Purified irradiated
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purified irradiated PfSPZ administered by needle inoculation in the skin
Trial: 21903775
Drug: Intravenous immunization
RxNorm normalized name: GLOBULIN,IMMUNE (IV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunization of PfSPZ
Trial: 21904098
Drug: MS-sNT (morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MS-sNT (morphine sulfate and sequestered naltrexone)
Trial: 21909835
Drug: Oral and
RxNorm normalized name: Tridate, oral and rectal kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral and intravenous levetiracetam (LEV)
Trial: 21911742
Drug: VLDL-TG storage
RxNorm normalized name: polyester-5 (TG-48)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VLDL-TG storage in upper-body subcutaneous (UBSQ) fat
Trial: 21911742
Drug: VLDL-TG storage
RxNorm normalized name: polyester-5 (TG-48)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VLDL-TG storage in lower-body subcutaneous (LBSQ) fat
Trial: 21911830
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of romidepsin, bortezomib, and dexamethasone
Trial: 21911830
Drug: Maintenance romidepsin
RxNorm normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Maintenance romidepsin 10 mg/m(2)
Trial: 21913066
Drug: Biologic agents
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biologic agents (monoclonal antibodies anti-TNF: infliximab and adalimumab; others: abatacept and tocilizumab)
Trial: 21915260
Drug: sirolimus, daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sirolimus, daily for 52 weeks
Trial: 21916630
Drug: Citalopram (antidepressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (antidepressant medication)
Trial: 21917896
Drug: Antiretroviral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral treatment with undetectable HIV RNA levels
Trial: 21921042
Drug: Baseline (before
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline (before hydroxyurea therapy)
Trial: 21921761
Drug: Carbon dioxide-based
RxNorm normalized name: Carbon Dioxide
DrugBank: Carbon dioxide (DB09157)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbon dioxide-based tissue expander with daily administration of small doses of carbon dioxide via a hand-held dosage controller.
Trial: 21923942
Drug: Postoperative epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative epidural infusion (EI) with ropivacaine 0.2% 3-8 mL/h and fentanyl 2 μg/mL
Trial: 21923942
Drug: Patient-controlled epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled epidural analgesia (PCEA) with ropivacaine/fentanyl bolus 1 mL, lock-out interval 12 min
Trial: 21923942
Drug: Intravenous fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous fentanyl 10 μg/ml postoperatively 3-8 mL/h (Control group)
Trial: 21927046
Drug: Interventional techniques
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interventional techniques with safe injection practices and single dose vials for multiple patients
Trial: 21930881
Drug: Oseltamivir 75
RxNorm normalized name: oseltamivir 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oseltamivir 75 mg by mouth twice daily
Trial: 21930881
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose of oseltamivir
Trial: 21931054
Drug: Pulsed-dye laser
RxNorm normalized name: amaranth dye
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed-dye laser treatment
Trial: 21931054
Drug: Triple combination
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple combination cream
Trial: 21931113
Drug: Dasatinib induction
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dasatinib induction therapy for 84 days combined with steroids for the first 32 days and intrathecal chemotherapy
Trial: 21931113
Drug: Dasatinib induction
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dasatinib induction therapy
Trial: 21931634
Drug: Intravenous bolus
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous bolus of E. coli lipopolysaccharide (LPS) 0.3 ng/kg
Trial: 21932952
Drug: Desirudin (Iprivask®,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desirudin (Iprivask®, Canyon Pharmaceuticals™)
Trial: 21935635
Drug: TSU-68, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TSU-68, a multiple tyrosine kinase inhibitor
Trial: 21935916
Drug: Eribulin 1.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eribulin 1.4 mg/m(2) administered intravenously on days 1 and 8 every 21 days in platinum-resistant cohort
Trial: 21935916
Drug: Eribulin 1.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eribulin 1.4 mg/m(2) administered intravenously on days 1 and 8 every 21 days in platinum-sensitive cohort
Trial: 21937277
Drug: Eribulin (1.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eribulin (1.4 mg/m² intravenously on days 1 and 8 every 3 weeks)
Trial: 21937701
Drug: Lenalidomide 25
RxNorm normalized name: lenalidomide 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide 25 mg/d on days 1-21 of a 28-day cycle
Trial: 21940838
Drug: Peginesatide (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peginesatide (various doses based on body weight or absolute doses, administered either intravenously or subcutaneously, every 4 or 2 weeks)
Trial: 21940838
Drug: Peginesatide (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peginesatide (various doses)
Trial: 21942531
Drug: SDP (SUMAVEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SDP (SUMAVEL DosePro) administered for ≤4 migraine attacks over ≤60 days
Trial: 21942991
Drug: Implementation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implementation of guidelines for systematic daily pain assessments following the educational intervention.
Trial: 21945953
Drug: Infliximab therapy
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab therapy discontinued
Trial: 21945953
Drug: Infliximab re-treatment
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab re-treatment after relapse
Trial: 21948234
Drug: Historical controls
RxNorm normalized name: typhus, historical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Historical controls (identically treated except for T1/T2 product infusions)
Trial: 21953248
Drug: Erlotinib 150
RxNorm normalized name: erlotinib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib 150 mg daily and bevacizumab 10 mg/kg on days 1 and 15 every 28 days
Trial: 21953853
Drug: Vitamin K
RxNorm normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K antagonist (VKA) therapy for patients with RVT for up to 2 years
Trial: 21953853
Drug: No VKA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No VKA therapy for patients without RVT
Trial: 21958326
Drug: B-type natriuretic
RxNorm normalized name: B-type natriuretic peptide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B-type natriuretic peptide (BNP) in TnT positive patients (TnT > 0.01 ng/mL) in the highest quartile (Q4)
Trial: 21964801
Drug: Panobinostat 10
RxNorm normalized name: panobinostat 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panobinostat 10 mg/m²
Trial: 21964801
Drug: Panobinostat 15
RxNorm normalized name: panobinostat 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panobinostat 15 mg/m²
Trial: 21964801
Drug: Panobinostat 20
RxNorm normalized name: panobinostat 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panobinostat 20 mg/m²
Trial: 21964801
Drug: Panobinostat (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panobinostat (all doses)
Trial: 21965374
Drug: DEX-brief (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEX-brief (2 mcg/kg bolus over 10 minutes)
Trial: 21965374
Drug: DEX-prolong (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEX-prolong (2 mcg/kg bolus plus 1 mcg/kg/hr infusion as needed)
Trial: 21967976
Drug: Intravenous clofarabine
RxNorm normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous clofarabine 40 mg/m(2) per day, cyclophosphamide 440 mg/m(2) per day, etoposide 100 mg/m(2) per day for 5 consecutive days
Trial: 21967976
Drug: Intravenous clofarabine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous clofarabine, cyclophosphamide, and etoposide
Trial: 21968545
Drug: Regadenoson (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regadenoson (0.4 mg/5 ml bolus)
Trial: 21968545
Drug: Adenosine (140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenosine (140 μg/kg/min)
Trial: 21969517
Drug: Nab-paclitaxel 125
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nab-paclitaxel 125 mg/m² plus gemcitabine 1,000 mg/m²
Trial: 21975221
Drug: Blood manganese
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood manganese levels in patients with hepatic encephalopathy (median, range) [28, (17-39.5) μg/L] for those who died after 6 months follow-up.
Trial: 21975221
Drug: Blood manganese
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood manganese levels in patients with hepatic encephalopathy (median, range) [13.5, (10.5-32) μg/L] for those who survived after 6 months follow-up.
Trial: 21975221
Drug: Blood manganese
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood manganese levels in patients with hepatic encephalopathy (median, range) [20.5, (10.5-39.5) μg/L].
Trial: 21976132
Drug: Dasatinib 50
RxNorm normalized name: dasatinib 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dasatinib 50 to 120 mg once daily and docetaxel 60 to 75 mg/m² every 21 days (phase 1)
Trial: 21976132
Drug: Dasatinib 100
RxNorm normalized name: dasatinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dasatinib 100 mg once daily and docetaxel 75 mg/m² every 21 days (phase 2)
Trial: 21976132
Drug: Single-agent dasatinib
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Single-agent dasatinib after docetaxel discontinuation
Trial: 21976540
Drug: Dovitinib (TKI258)
RxNorm normalized name: Dovitinib
DrugBank: Dovitinib (DB05928)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dovitinib (TKI258) at 400 mg/d
Trial: 21976672
Drug: Barasertib 1200
RxNorm normalized name: Barasertib
DrugBank: Barasertib (DB11747)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Barasertib 1200 mg
Trial: 21976672
Drug: Barasertib 800
RxNorm normalized name: Barasertib
DrugBank: Barasertib (DB11747)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Barasertib 800 mg, 1200 mg, and 1600 mg
Trial: 21977353
Drug: Desvenlafaxine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desvenlafaxine (200 to 400 mg/d)
Trial: 21977355
Drug: Physician counseling
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Physician counseling that medication use was safe despite FDA warning
Trial: 21982650
Drug: Real-world treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Real-world treatment including rate and rhythm control, stroke prevention, transitions to new therapies
Trial: 21983216
Drug: PCV13 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCV13 (2 doses for group 1, 1 dose for group 2)
Trial: 21986722
Drug: Carboplatin (AUC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin (AUC 4 mg/ml-min), Irinotecan (340 mg/m2 for patients on EIAEDs, 125 mg/m2 for others), Bevacizumab (10 mg/kg)
Trial: 21986736
Drug: Proinflammatory sex
RxNorm normalized name: Arthriten Inflammatory Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proinflammatory sex hormone profile (low testosterone and high estradiol)
Trial: 21987241
Drug: Maraviroc 150
RxNorm normalized name: maraviroc 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maraviroc 150 mg twice daily for 14 days
Trial: 21991891
Drug: Inhaled glucocorticoids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled glucocorticoids
Trial: 21991892
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with bronchodilator reversibility
Trial: 21992630
Drug: Zilver PTX
RxNorm normalized name: PTX-100
DrugBank: PTX-100 (DB18125)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zilver PTX drug-eluting stent
Trial: 21992853
Drug: Aflibercept 6
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aflibercept 6 mg/kg intravenously plus docetaxel 75 mg/m(2) intravenously, every 3 weeks
Trial: 21993671
Drug: Phlebotomy therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phlebotomy therapy in VHL(R200W) homozygotes
Trial: 21994418
Drug: ALT-801 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALT-801 at 0.04 mg/kg
Trial: 21994418
Drug: ALT-801 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ALT-801 treatment
Trial: 21998698
Drug: RTS,S/AS01(E) vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTS,S/AS01(E) vaccine
Trial: 21999176
Drug: Prefilled pen
RxNorm normalized name: Byetta Prefilled Pen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prefilled pen for IM IFNβ-1a administration
Trial: 22002941
Drug: Methylation-promoting dietary
RxNorm normalized name: methylal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylation-promoting dietary supplements (betaine, metafolin, creatine, and vitamin B(12))
Trial: 22003383
Drug: NMRC-M3V-Ad-PfCA vaccine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NMRC-M3V-Ad-PfCA vaccine, 2×10^10 particle units (1×10^10 each construct)
Trial: 22003383
Drug: NMRC-M3V-Ad-PfCA vaccine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NMRC-M3V-Ad-PfCA vaccine, 5-fold higher dose (10×10^10 particle units)
Trial: 22003383
Drug: NMRC-M3V-Ad-PfCA vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NMRC-M3V-Ad-PfCA vaccine
Trial: 22003411
Drug: NMRC-MV-Ad-PfC vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NMRC-MV-Ad-PfC vaccine (adenovirus vector encoding CSP), 1 x 10^10 particle units per dose, two doses 16 weeks apart
Trial: 22003411
Drug: NMRC-MV-Ad-PfC vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NMRC-MV-Ad-PfC vaccine (adenovirus vector encoding CSP)
Trial: 22004373
Drug: Non-surgical treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-surgical treatment by a doctor
Trial: 22005144
Drug: Perioperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative chemotherapy (PCT) with surgery, based mainly on a fluorouracil-platinum doublet or triplet regimen.
Trial: 22005144
Drug: Primary surgery
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary surgery (S) without perioperative chemotherapy.
Trial: 22005144
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy after surgery in the S group.
Trial: 22005144
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy after surgery in the PCT group.
Trial: 22005144
Drug: PCT as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCT as a treatment.
Trial: 22006233
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of autologous platelet-rich fibrin matrix (PRFM) into the deep dermis and subdermis of the skin.
Trial: 22008340
Drug: Topical rThrombin
RxNorm normalized name: rThrombin
DrugBank: rhThrombin (DB04923)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical rThrombin applied as a hemostatic aid during surgical procedure (day 1)
Trial: 22011412
Drug: Autologous umbilical
RxNorm normalized name: Autologous umbilical cord blood
DrugBank: Autologous cord blood (DB17926)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous umbilical cord blood (UCB) infusion
Trial: 22011459
Drug: FDG PET/CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDG PET/CT after one cycle of neoadjuvant chemotherapy
Trial: 22012004
Drug: Genexol-PM 240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genexol-PM 240 mg/m(2) intravenously over 3 h every 3 weeks, with intra-patient dose escalation to 300 mg/m(2) allowed if no pre-specified toxicities were observed.
Trial: 22013821
Drug: Paper-based prescriptions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paper-based prescriptions (control group)
Trial: 22014006
Drug: Pazopanib and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib and metronomic oral cyclophosphamide
Trial: 22015991
Drug: Sorafenib dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib dose escalation to 600 mg BID through cycle 2
Trial: 22015991
Drug: Sorafenib dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib dose re-escalation to 400 mg BID through cycle 3
Trial: 22015991
Drug: Completion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Completion of cycle 1 without dose modification or discontinuing treatment
Trial: 22015991
Drug: Primary dose
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary dose escalation through cycle 2
Trial: 22018074
Drug: Daily vitamin
RxNorm normalized name: Daily Vitamin Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily vitamin D supplementation
Trial: 22021722
Drug: Amoxicillin and
RxNorm normalized name: omeprazole, amoxicillin and rifabutin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin and Clavulanic Acid (antibiotic therapy)
Trial: 22021788
Drug: Tight glycaemic
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tight glycaemic control (intravenous, then subcutaneous insulin to control blood glucose to 4.4-6.5 mmol/l)
Trial: 22021870
Drug: Manual Physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual Physical Therapy (MPT) - 6 sessions
Trial: 22021870
Drug: Corticosteroid Injections
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid Injections (CSI) - 1 to 3 sessions
Trial: 22021873
Drug: Viusid (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viusid (three oral sachets daily, n=50)
Trial: 22024527
Drug: HIV RNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV RNA ≥ 4 log₁₀ copies/ml at failure.
Trial: 22025149
Drug: R1507 9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R1507 9 mg/kg intravenously once a week
Trial: 22025149
Drug: R1507 27
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R1507 27 mg/kg intravenously every three weeks
Trial: 22025151
Drug: Neoadjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant therapy with oxaliplatin 85 mg/m(2) on days 1, 15, and 29; protracted-infusion fluorouracil (PI-FU) 180 mg/m(2)/d on days 8 through 43; external-beam radiation therapy (EBRT) 5 days a week at 1.8 Gy/d for 25 fractions
Trial: 22025151
Drug: Neoadjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant therapy with oxaliplatin, PI-FU, and EBRT
Trial: 22025154
Drug: Figitumumab at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Figitumumab at 30 mg/kg intravenously every 4 weeks for a median of 2 cycles (range, 1 to 16)
Trial: 22025154
Drug: Figitumumab at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Figitumumab at 30 mg/kg with baseline free IGF-1 ≥ 0.65 ng/mL
Trial: 22025154
Drug: Figitumumab at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Figitumumab at 30 mg/kg with pretreatment circulating free IGF-1 lower than 0.65 ng/mL
Trial: 22025196
Drug: Leuprolide acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide acetate 45 mg 6-month depot
Trial: 22025778
Drug: Presence of
RxNorm normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presence of crown-like structures (CLS) in subcutaneous adipose tissue (n = 16)
Trial: 22028492
Drug: L19-IL2 in
RxNorm normalized name: DAB(SUB 389)IL2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L19-IL2 in combination with dacarbazine